CORRECTION Open Access

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT



Vibeke Strand¹, Janet Pope², Namita Tundia^{3*}, Alan Friedman³, Heidi S. Camp³, Aileen Pangan³, Arijit Ganguli³, Mahesh Fuldeore³, Debbie Goldschmidt⁴ and Michael Schiff⁵

Correction to: Arthritis Res Ther (2019)21:272 https://doi.org/10.1186/s13075-019-2037-1

Following publication of the original article [1], the authors reported an error in some of the data values in Fig. 2a. The correct Fig. 2a can be seen below.

Author details

¹Stanford University, Palo Alto, CA, USA. ²University of Western Ontario, London, ON, Canada. ³AbbVie Inc., North Chicago, IL, USA. ⁴Analysis Group, Inc., New York, NY, USA. ⁵University of Colorado, Denver, CO, USA.

Published online: 09 June 2020

Reference

 Strand V, Pope J, Tundia N, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21:272 https://doi.org/10.1186/s13075-019-2037-1.

The original article can be found online at https://doi.org/10.1186/s13075-019-2037-1.

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: namita.tundia@abbvie.com

³AbbVie Inc., North Chicago, IL, USA




Fig. 2 Percentage of patients reporting improvements ≥ MCID at week 12. a Patient's Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), morning (AM) joint stiffness duration, AM stiffness severity, Work Instability Scale for RA (RA-WIS), and Short Form 36 Health Survey (SF-36)